Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation

<p><strong>Background</strong></p> <p>The TWO Study (Transplantation Without Overimmunosuppression) aimed to investigate a novel approach to regulatory T-cell (Treg) therapy in renal transplant patients, using a delayed infusion protocol at 6 mo posttransplant to promot...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Brook, MO, Hennessy, C, Hester, J, Hammad, S, Alzhrani, A, Rombach, I, Dutton, S, Lombardi, G, Wood, KJ, Friend, P, Harden, PN, Issa, F
Định dạng: Journal article
Ngôn ngữ:English
Được phát hành: Wolters Kluwer 2024

Những quyển sách tương tự